Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

I C U Medical Inc (NQ: ICUI )

98.94 -0.11 (-0.11%)
Streaming Delayed Price Updated: 12:24 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about I C U Medical Inc

< Previous 1 2 3 Next >
ICU Medical's Earnings: A Preview
Via Benzinga
ICU Medical to Present at the Raymond James 44th Annual Institutional Investors Conference
From ICU Medical, Inc.
Via GlobeNewswire
ICU Medical Announces Time of Fourth Quarter 2022 Earnings Conference Call
From ICU Medical, Inc.
Via GlobeNewswire
ICU Medical to Present at the J.P. Morgan 41st Annual Healthcare Conference
From ICU Medical, Inc.
Via GlobeNewswire
ICU Medical's Return On Capital Employed Insights
Via Benzinga
FDA Signals Shortage Of ICU Medical's Tracheostomy Tubes
Via Benzinga
Smiths Acquisition Weighs On ICU Medical's Profitability, Shares Fall
Via Benzinga
TC BioPharm Ltd ($TCBP) leads fight against Acute myeloid leukemia with its cell therapy product OmnImmune
Via AB Newswire
Topics Death Economy Stocks
Exposures COVID-19 Death Interest Rates
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
ICU Medical Announces Third Quarter 2022 Results
The Company Reaffirms 2022 Fiscal Year Guidance 
From ICU Medical, Inc.
Via GlobeNewswire
Expert Ratings for ICU Medical
  Analysts have provided the following ratings for ICU Medical (NASDAQ:ICUI) within the last quarter: 
Via Benzinga
ICU Medical: Q2 Earnings Insights
  ICU Medical (NASDAQ:ICUI) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca's COVID-19 Shot, Tesla Eyes Cybertruck Commercialization From Next Year: Top Stories Tuesday, Nov. 01
Bloomberg Tesla Migrates Shanghai Factory Workers To Boost US Plant Production 
Via Benzinga
ICU Medical Announces Time of Third Quarter 2022 Earnings Conference Call
From ICU Medical, Inc.
Via GlobeNewswire
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
This Analyst Lowers Price Target On Lyft; Also Check Out Some Other Major PT Changes
Wells Fargo cut the price target on Lyft, Inc. (NASDAQ: LYFT) from $49 to $42. However, Wells Fargo analyst Brian Fitzgerald maintained the stock with an Overweight. Lyft shares rose 0.6% to $20.41 in... 
Via Benzinga
Raymond James Says 'Supply Chain Challenges Made Q1 Messy' For This Medtech Stock
Via Benzinga
Micron Technology, Novavax, CarGurus And Some Other Big Losers From Tuesday
U.S. stocks closed lower, with the Nasdaq dropping 150 points on Tuesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
ICU Medical's Return On Capital Employed Insights
ICU Medical (NASDAQ:ICUI) brought in sales totaling $543.12 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 291.06%, resulting in a loss of $38.07 million. 
Via Benzinga
Morgan Stanley And 2 Other Stocks Insiders Are Buying
Although US stocks closed sharply higher on Friday, there were a few notable insider trades. 
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading. 
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
UnitedHealth, Vertex Lead Five Stocks Looking Healthy In A Weak Market
Health care stocks have some advantages in the current market environment. 
Via Investor's Business Daily
Recap: ICU Medical Q4 Earnings
ICU Medical (NASDAQ:ICUI) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ICU... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name... 
Via Benzinga
ICU Medical, inc (ICUI) Q3 2021 Earnings Call Transcript
ICUI earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.